Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy

Am J Gastroenterol. 2000 Feb;95(2):457-62. doi: 10.1111/j.1572-0241.2000.01768.x.

Abstract

Objective: Opportunistic disorders (OD) are the most frequent GI manifestations of the acquired immunodeficiency syndrome (AIDS). Since the introduction of highly active antiretroviral therapy (HAART), there appears to be have been a reduction in the incidence of many of these OD; however, the effect of HAART on the prevalence of GI OD has not been well studied.

Methods: From 4/95 through 3/98, all HIV (HIV)-infected patients undergoing GI endoscopy were prospectively identified; mucosal biopsies were obtained in a standardized fashion and histological specimens were examined by a single GI pathologist. Patients were divided into three groups based on the time of evaluation: group I: 4/95 to 3/96; group II: 4/96 to 3/97; and group III: 4/97 to 3/98.

Results: A total of 166 patients (90% men; mean age 36+/-10 yr; median CD4 lymphocyte count 62 cells/microl, range 2-884, median viral RNA level 1,357 copies/ml, range undetectable to 7,721,715) underwent 279 upper and/or lower endoscopies during the study period. There were no statistical differences in patients' demographics and indications for endoscopy although the CD 4 lymphocyte count was higher in group III. The percentage of patients receiving HAART at the time of endoscopy increased from 0% to 57% over the three periods (p<0.01), and the percentage of patient receiving combination antiretroviral therapy increased from 37% to 82% over the study period (p<0.01). In contrast, the prevalence of OD decreased from 69% (group I) to 13% (group III) (p<0.01), whereas the prevalence of non-OD, including a normal endoscopy increased from 31% to 87% (p<0.01).

Conclusions: GI OD now seem to be an uncommon problem in HIV-infected patients undergoing endoscopy despite a low CD4 lymphocyte count, and this reduction of OD was associated with the use of HAART.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / epidemiology*
  • AIDS-Related Opportunistic Infections / prevention & control
  • Acquired Immunodeficiency Syndrome / drug therapy
  • Adult
  • Alabama / epidemiology
  • Anti-HIV Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Cohort Studies
  • Endoscopy, Gastrointestinal
  • Female
  • Follow-Up Studies
  • Gastric Mucosa / pathology
  • Gastrointestinal Diseases / epidemiology*
  • Gastrointestinal Diseases / prevention & control
  • HIV / genetics
  • HIV Infections / drug therapy
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Intestinal Mucosa / pathology
  • Male
  • Prevalence
  • Prospective Studies
  • RNA, Viral / blood
  • Viral Load

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • RNA, Viral